摘要
对36例高甘油三酯（TG）并糖调节受损或空腹血糖≤8.0 mmol/L新诊断2型糖尿病患者,行3个月非诺贝特治疗.治疗后患者血脂水平改善,早时相胰岛素生成指数及急性胰岛素反应增加（98.9比129.2,3558.9比4783.3 pmol·L-1·min-1,均P＜0.05）;空腹胰岛素、稳态模型胰岛素抵抗指数显著下降（128.6比84.8 pmol/L,4.8比3.0,均P＜0.05）;TG高值组（TG＞3.3 mmol/L）治疗后胰岛β细胞功能改善更为明显.说明非诺贝特短期调脂治疗可改善胰岛β细胞功能、减轻胰岛素抵抗,TG水平高者获益更明显.
Thirty six patients with hypertriglyceridemia and impaired glucose regulation or newly diagnosed type 2 diabetes, whose fasting plasma glucose was ≤8.0 mmol/L, were treated by fenofibrate for 3 months. Lipid profile, insulin during intravenous glucose tolerance test and oral glucose tolerance test （ including glucose） were measured before and after treatment After treatment, lipid profile was significantly improved. Insulinogenic index （△I30/△G30） and acute insulin response were significantly increased （98. 9vs. 129. 2, 3558.9 vs. 4783. 3 pmol · L - 1 · min - 1, respectively, P ＜ 0. 05 ）. Fasting insulin and insulin resistant index in homeostasis model assessment （ HOMA IR） decreased （ 128. 6 vs. 84. 8 pmol/L, 4. 8 vs.3.0, respectively, P ＜0. 05 ）. The improvement of insulin secretory function was more significant in patients with higher triglyceride （TG ＞ 3. 3 mmol/L）. These results indicate that short-term lipid-lowering treatment with fenofibrate can improve β-cell function and insulin resistance. Patients with higher triglyceride are likely to achieve more benefit from lipid-lowering treatment.
出处
《中华全科医师杂志》
2010年第9期645-647,共3页
Chinese Journal of General Practitioners
基金
广东省自然科学基金重点项目（925100891000030）
＂863＂计划子课题（2006AA02A409）
